SEI Investments’s Takeda Pharmaceutical TAK Stock Holding History

SEI Investments’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.39M	Sell	211,534 -18,409	-8%	-$305K	﹤0.01%	1687
2026 Q1	$4.26M	Buy	229,943 +38,740	+20%	+$680K	﹤0.01%	1629
2025 Q4	$2.98M	Sell	191,203 -2,096	-1%	-$30K	﹤0.01%	1658
2025 Q3	$2.83M	Buy	193,299 +33,362	+21%	+$495K	﹤0.01%	1557
2025 Q2	$2.47M	Buy	159,937 +10,129	+7%	+$150K	﹤0.01%	1567
2025 Q1	$2.23M	Sell	149,808 -73,079	-33%	-$1.02M	﹤0.01%	1596
2024 Q4	$2.95M	Sell	222,887 -93,071	-29%	-$1.28M	﹤0.01%	1520
2024 Q3	$4.49M	Sell	315,958 -17,782	-5%	-$252K	0.01%	1335
2024 Q2	$4.32M	Sell	333,740 -39,235	-11%	-$519K	0.01%	1292
2024 Q1	$5.18M	Buy	372,975 +23,525	+7%	+$342K	0.01%	1205
2023 Q4	$4.99M	Sell	349,450 -12,030	-3%	-$171K	0.01%	1191
2023 Q3	$5.59M	Buy	361,480 +34,787	+11%	+$539K	0.01%	1109
2023 Q2	$5.13M	Buy	326,693 +14,069	+5%	+$231K	0.01%	1181
2023 Q1	$5.15M	Sell	312,624 -16,288	-5%	-$259K	0.01%	1174
2022 Q4	$5.13M	Buy	328,912 +14,872	+5%	+$208K	0.01%	1037
2022 Q3	$4.07M	Buy	314,040 +12,127	+4%	+$169K	0.01%	1189
2022 Q2	$4.18M	Buy	301,913 +39,533	+15%	+$564K	0.01%	1185
2022 Q1	$3.73M	Sell	262,380 -39,529	-13%	-$580K	0.01%	1260
2021 Q4	$4.1M	Sell	301,909 -24,711	-8%	-$347K	0.01%	1240
2021 Q3	$5.34M	Sell	326,620 -4,575	-1%	-$76.8K	0.01%	1053
2021 Q2	$5.57M	Buy	331,195 +65,824	+25%	+$1.12M	0.01%	1021
2021 Q1	$4.83M	Hold	265,371	–	–	0.01%	1033
2020 Q4	$4.83M	Buy	265,371 +52,612	+25%	+$923K	0.01%	988
2020 Q3	$3.83M	Sell	212,759 -74,260	-26%	-$1.35M	0.01%	994
2020 Q2	$5.17M	Sell	287,019 -66,651	-19%	-$1.2M	0.02%	847
2020 Q1	$5.4M	Buy	353,670 +7,667	+2%	+$139K	0.02%	718
2019 Q4	$6.81M	Sell	346,003 -20,118	-5%	-$385K	0.02%	750
2019 Q3	$6.32M	Sell	366,121 -13,089	-3%	-$226K	0.02%	821
2019 Q2	$6.71M	Buy	379,210 +54,805	+17%	+$997K	0.02%	784
2019 Q1	$6.59M	Buy	324,405 +36,174	+13%	+$728K	0.02%	766
2018 Q4	$4.88M	Buy	+288,231	New	+$4.87M	0.02%	912

Other funds holding TAK

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

SEI Investments's TAK Position: Q2 2026 in Review

SEI Investments reduced its Takeda Pharmaceutical (TAK) stake by 8% in Q2 2026, selling an estimated $305K and leaving 211,534 shares worth $3.39M. The position accounts for ﹤0.01% of the portfolio, ranked #1687.

SEI Investments first reported a position in TAK in Q4 2018 and has held it in 31 quarters since. The position peaked at $6.81M in Q4 2019. 376 funds tracked by Wall St. Rank hold TAK as of Q2 2026.

SEI Investments held 211,534 shares of Takeda Pharmaceutical worth $3.39M as of Q2 2026.
SEI Investments sold 18,409 Takeda Pharmaceutical shares in Q2 2026, an estimated $305K.
Takeda Pharmaceutical made up ﹤0.01% of SEI Investments's portfolio in Q2 2026, its #1687 holding.
SEI Investments first reported a position in Takeda Pharmaceutical in Q4 2018 and has held it in 31 quarters since.
SEI Investments's Takeda Pharmaceutical position peaked at $6.81M in Q4 2019.
376 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2026.

Based on SEI Investments's 13F filing for Q2 2026, filed 14 Aug 2026.